Daniele Pastori

Prof. Daniele Pastori

Department of Clinical, Internal, Anaesthetic and Cardiovascular Sciences. Sapienza University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
GCGuido CARPINO
Guido CARPINO
MBMaria Del Ben
Maria Del Ben
Daniele PastoriDaniele Pastori
Daniele Pastori
RCRoberto Carnevale
Roberto Carnevale
FBFrancesco Baratta
Francesco Baratta
FVFrancesco Violi
Francesco Violi


Verified
Journal Article
Open access
PDF file
Daniele PastoriDaniele Pastori
Daniele Pastori
VCVito Maria Cormaci
Vito Maria Cormaci
SMSilvia Marucci
Silvia Marucci
GFGiovanni Franchino
Giovanni Franchino
FSFrancesco Del Sole
Francesco Del Sole
PPPasquale Pignatelli
Pasquale Pignatelli
Venous thromboembolism (VTE) is the third most common cause of death worldwide. The incidence of VTE varies according to different countries, ranging from 1–2 per 1000 person-years in Western Countries, while it is lower in Eastern Countries (70 per 1000 person-years) and lowest in breast, melanoma and prostate cancer (<20 per 1000 person-years). In this comprehensive review, we summarized the prevalence of different risk factors for VTE and the potential molecular mechanisms/pathogenetic mediators leading to VTE.

1 September 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
FBFrancesco Baratta
Francesco Baratta
Daniele PastoriDaniele Pastori
Daniele Pastori
FAFrancesco Angelico
Francesco Angelico
Andrea BallaAndrea Balla
Andrea Balla
APAlessandro Maria Paganini
Alessandro Maria Paganini
MBMaria Del Ben
Maria Del Ben

10 April 2018 in Polish Heart Journal
Verified
Journal Article
Closed access
PDF file
PPPasquale Pignatelli
Pasquale Pignatelli
DMDanilo Menichelli
Danilo Menichelli
Daniele PastoriDaniele Pastori
Daniele Pastori
FVFrancesco Violi
Francesco Violi
The role of oxidative stress in the onset and progression of atherosclerosis and its impact on the development of cardiovascular events has been widely described. Thus, increased oxidative stress has been described in several atherosclerotic risk factors, such as hypertension, dyslipidaemia, peripheral artery disease, metabolic syndrome, diabetes, and obesity. Among others, specific oxidative pathways involving both pro-oxidant and antioxidant enzymes seem to play a major role in the production of reactive oxidant species (ROS), such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, myeloperoxidase, superoxide dismutase, and glutathione peroxidase. In this review, we will discuss: 1) the most relevant enzyme systems involved in the formation and detoxification of ROS, 2) the relationship between oxidative stress and cardiovascular risk, and 3) therapeutic implications to modulate oxidative stress. The role of oxidative stress in the onset and progression of atherosclerosis and its impact on the development of cardiovascular events has been widely described. Thus, increased oxidative stress has been described in several atherosclerotic risk factors, such as hypertension, dyslipidaemia, peripheral artery disease, metabolic syndrome, diabetes, and obesity. Among others, specific oxidative pathways involving both pro-oxidant and antioxidant enzymes seem to play a major role in the production of reactive oxidant species (ROS), such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, myeloperoxidase, superoxide dismutase, and glutathione peroxidase. In this review, we will discuss: 1) the most relevant enzyme systems involved in the formation and detoxification of ROS, 2) the relationship between oxidative stress and cardiovascular risk, and 3) therapeutic implications to modulate oxidative stress.

29 April 2020 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
FVFrancesco Violi
Francesco Violi
Daniele PastoriDaniele Pastori
Daniele Pastori
Roberto CangemiRoberto Cangemi
Roberto Cangemi
PPPasquale Pignatelli
Pasquale Pignatelli
Lorenzo LoffredoLorenzo Loffredo
Lorenzo Loffredo
The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment.